Lutetium Lu 177 dotatate

Lutetium Lu 177 dotatate is a targeted radiotherapy used to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are neuroendocrine tumors (NETs) that develop in the gastrointestinal tract and pancreas. Lutetium Lu 177 dotatate delivers targeted radiation directly to the neuroendocrine tumors to slow tumor progression. The treatment is given every 8 weeks for 4 doses.

Lutetium Lu 177 dotatate is available under 3 brand names in the US:

• Lutathera by Novartis (Advanced Accelerator Applications), the original (reference) product, first approved in 2018.
• Bexlutry by Curium, approved in September 2026 through the FDA's 505(b)(2) pathway, which allows approval based partly on published evidence and data for a previously approved product.
• Bravnetsa by Lantheus, approved on September 22, 2026, through the FDA's Abbreviated New Drug Application (ANDA) pathway. The FDA determined Bravnetsa to be bioequivalent and therapeutically equivalent to Lutathera.

Lutetium Lu 177 dotatate is FDA-approved to treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are:

• in the foregut, midgut, or hindgut
• somatostatin receptor-positive.

Lutathera is approved for adults and children aged 12 years and older. Bexlutry and Bravnetsa are approved for adults only. Pediatric use information is approved for Lutathera, but because of Lutathera's marketing exclusivity rights, Bexlutry and Bravnetsa are not labeled with that pediatric information.

Lutetium Lu 177 dotatate is a targeted treatment designed for certain types of tumors that have somatostatin receptors on their surface. These receptors act like docking stations that lutetium Lu 177 dotatate can latch onto. Once the drug attaches, it delivers a small, controlled dose of radiation directly to the tumor cells.

Lutetium Lu 177 dotatate works in three key steps:

• Finding the tumor: Lutetium Lu 177 dotatate recognizes and binds to somatostatin receptors, with the highest affinity for subtype 2 (SSTR2), which are commonly found on neuroendocrine tumor cells.
• Delivering radiation: Once bound, the drug is taken inside the cell. It carries a radioactive component, lutetium-177, which emits beta radiation.
• Targeted cell destruction: The radiation forms free radicals that damage the tumor cells and neighboring cells, causing them to die.

Lutetium Lu 177 dotatate is a radiolabeled somatostatin analog. It is from a class of medicines called peptide receptor radionuclide therapy (PRRT).

The FDA labels for all three brands (Lutathera, Bexlutry, and Bravnetsa) are based on the same lutetium-177 dotatate clinical studies. The main trial was NETTER-1 (NCT01578239), which compared lutetium Lu 177 dotatate plus long-acting octreotide with high-dose long-acting octreotide in 229 adults with progressive, somatostatin receptor-positive midgut carcinoid tumors. A later trial, NETTER-2 (NCT03972488), studied lutetium Lu 177 dotatate as a first treatment in adults with newly diagnosed, advanced grade 2 or 3 GEP-NETs.

In the final NETTER-1 analysis, there was no statistically significant difference in overall survival between the two groups. In a separate study (ERASMUS) of 360 patients with foregut, midgut, and hindgut GEP-NETs, the overall response rate was 17%.

Embryo-fetal toxicity: Do not become pregnant or breastfeed a baby while receiving lutetium Lu 177 dotatate.

Both men and women using lutetium Lu 177 dotatate should use effective birth control to prevent pregnancy. Lutetium Lu 177 dotatate can harm an unborn baby or cause birth defects if the mother or father is using this medicine.

Other warnings include:

• Risk from radiation exposure
• Myelosuppression (low blood cell counts)
• Secondary myelodysplastic syndrome (MDS) and leukemia
• Renal toxicity
• Hepatotoxicity
• Hypersensitivity reactions, including angioedema
• Neuroendocrine hormonal crisis
• Risk of infertility

Tell your doctor if you have ever had:

• kidney disease;
• liver disease, including cancer that has spread to the liver;
• diabetes;
• high blood pressure;
• an allergic reaction to lutetium Lu 177 dotatate; or
• any type of radiation treatment.

Lutetium Lu 177 dotatate may cause other types of cancer, such as leukemia. Ask your doctor about this risk.

Breastfeeding

Do not breastfeed while receiving lutetium Lu 177 dotatate, and for 2.5 months after your last dose.

Pregnancy

You should not use lutetium Lu 177 dotatate cancer treatment if you are pregnant or planning a pregnancy. Your doctor will check that you are not pregnant before you start treatment.

Lutetium Lu 177 dotatate treatment can harm an unborn baby or cause birth defects if the mother or the father is receiving this medicine.

• If you are a woman, use effective birth control to prevent pregnancy while you are receiving this medicine and for 7 months after your last dose.
• If you are a man, use effective birth control if your sex partner can get pregnant. Keep using birth control for 4 months after your last dose.
• Tell your doctor right away if a pregnancy occurs while either the mother or the father is receiving lutetium Lu 177 dotatate.

Fertility

This medicine may affect fertility (ability to have children) in both men and women. However, it is important to use birth control to prevent pregnancy because lutetium Lu 177 dotatate may harm the baby if a pregnancy does occur.

Common side effects of lutetium Lu 177 dotatate

Common lutetium Lu 177 dotatate side effects may include:

• Nausea 65%
• Vomiting 53%
• Tiredness (fatigue) 38%
• Diarrhea 26%
• Abdominal pain 26%
• Decreased appetite 21%
• Headache 17%
• Dizziness 17%
• Swelling in the hands, ankles, or feet (peripheral edema) 16%

These were the common side effects that occurred in 15% or more of patients receiving lutetium Lu 177 dotatate in the NETTER-1 clinical trial. Laboratory abnormalities were also a common side effect of this medicine, including lymphopenia, anemia, leukopenia, thrombocytopenia, neutropenia, increased creatinine, hyperglycemia, hyperuricemia, increased GGT, increased alkaline phosphatase and many more.

Serious lutetium Lu 177 dotatate side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. You will be watched closely for at least 2 hours after each infusion for signs of an allergic reaction.

Lutetium Lu 177 dotatate treatment may cause other serious side effects. Call your doctor at once if you have:

• little or no urination;
• flushing (warmth, redness, or tingly feeling);
• diarrhea;
• a light-headed feeling, like you might pass out;
• wheezing, chest tightness, trouble breathing;
• low blood cell counts: fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath; or
• low potassium level: cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness, or limp feeling.

Your lutetium Lu 177 dotatate cancer treatments may be delayed, given at a lower dose, or permanently discontinued if you have certain side effects.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Lutetium Lu 177 dotatate is given as an infusion into a vein. A healthcare provider will give you this infusion once every 8 weeks for a total of 4 doses. The usual adult dose is 7.4 GBq (200 mCi) per infusion.

Lutetium Lu 177 dotatate must be given slowly, and the infusion can take 30 to 40 minutes to complete.

Before each infusion, you will be given medicine to prevent nausea and vomiting. An amino acid solution is also given into a vein, starting 30 minutes before the lutetium Lu 177 dotatate infusion and continuing during and for at least 3 hours after it. This helps protect your kidneys from radiation.

After each infusion, you will be given another medicine called octreotide, which is injected into a muscle 4 to 24 hours after your dose. Octreotide injections are then usually given once every 4 weeks after you finish lutetium Lu 177 dotatate treatment, for up to 18 months from the start of treatment.

You may be given other medications to help prevent serious side effects or allergic reactions. Keep using these medicines for as long as your doctor has prescribed.

Drink plenty of fluids and urinate often before, on the day of, and the day after each infusion, to help keep your kidneys working properly.

You will need frequent blood tests to check your blood cell counts, kidney function and liver function. Your cancer treatments may be delayed or your dose lowered based on the results.

For up to 30 days after you are treated with lutetium Lu 177 dotatate, your urine will contain radiation. To prevent the spread of this radiation, use a toilet rather than a urinal, and sit on the toilet while urinating.

Always wash your hands after using the bathroom. Avoid handling any clean-up of your stools or urine without wearing latex rubber gloves. If another person is handling your urine, they should wear gloves, eye protection, and a mask to cover the nose and mouth.

When cleaning any spills of bodily fluid, use only disposable cleaning cloths that can be flushed down a toilet. Ask your doctor or health department how to dispose of any bodily fluid spills that cannot be flushed down a toilet.

Wash any soiled clothing separately from the laundry of other people in your home.

Call your doctor for instructions if you miss an appointment for your lutetium Lu 177 dotatate infusion.

Since lutetium Lu 177 dotatate is given by a healthcare professional in a medical setting, an overdose is unlikely to occur.

Somatostatin analogs: Medicines such as octreotide and lanreotide bind to the same receptors as lutetium Lu 177 dotatate and may make it less effective. Long-acting somatostatin analogs should be stopped at least 4 weeks, and short-acting octreotide at least 24 hours, before each lutetium Lu 177 dotatate dose.

Steroid medicines (glucocorticoids): Repeated high doses of steroid medicines should be avoided during treatment, because they can reduce the number of somatostatin receptors on tumor cells.

Other drugs may affect lutetium Lu 177 dotatate, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

This list of interactions may not be complete and other interactions may occur.

HCPs and patients often use the prescribing information for more detailed information about this medicine:

• Lutathera Prescribing Information
• Bexlutry Prescribing Information
• Bravnetsa Prescribing Information

The prescribing information (PI) contains more comprehensive information on Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies, Drug Interactions, and more. Discuss any medical questions you have with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.

The prescribing information is also known as the package insert or the FDA label.

• Lutathera: Novartis AG (registered trademark). Distributed by Advanced Accelerator Applications USA, Inc., Millburn, NJ 07041.
• Bexlutry: Manufactured by Curium US LLC, Noblesville, IN 46060.
• Bravnetsa: Manufactured by Point Biopharma USA Inc., Indianapolis, IN 46268. Distributed by Lantheus Medical Imaging, N. Billerica, MA 01862.